Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation.
The JAK2 V617F point mutation is very rare in hypereosinophilic syndrome and/or chronic eosinophilic leukemia. Here we report on a patient with chronic eosinophilic leukemia and detectable JAK2 mutant clone, who achieved a good molecular response to interferon alpha-2a after 4 months of treatment. The molecular response correlated with only moderate haematological improvement.
Helbig
G
G
Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, 40-027 Katowice, Dabrowski str. 25, Poland. ghelbig@o2.pl
Stella-Holowiecka
B
B
Majewski
M
M
Lewandowska
M
M
Holowiecki
J
J
D002908:Chronic Disease; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D053614:Janus Kinase 2